Claims
- 1) A suspension of crystalline tiotropium bromide monohydrate in propellant gases HFA 227 and/or HFA 134a, optionally in admixture with one or more other propellant gases chosen from propane, butane, pentane, dimethylether, CHClF2, CH2F2, CF3CH3, isobutane, isopentane and neopentane.
- 2) The suspension according to claim 1, wherein the amount of tiotropium bromide is between 0.001 and 0.8%.
- 3) The suspension according to claim 2, further containing other ingredients chosen from surfactants, adjuvants, antioxidants and flavourings or combinations thereof.
- 4) The suspension according to claim 3, wherein the surfactants are one or more compounds chosen from Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropylmyristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyl oleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monosterate, glyceryl monoricinoleate, cetylalcohol, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, ethanol and isopropanol or combinations thereof.
- 5) The suspension according to claim 3, wherein the adjuvants are one or more compounds chosen from alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulphuric acid and citric acid or combinations thereof.
- 6) The suspension according to claim 3, wherein the antioxidants are one or more compounds chosen from ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbyl palmitate or combinations thereof.
- 7) The suspension according to claim 1 or 2, wherein they contain no other ingredients apart from the active substance and the propellant gas or gases.
- 8) A method of treating a disease, said disease being chosen from those in which an anticholinergic confers a therapeutic benefit, said method comprising administering by inhalation or nasal route to a patient in need thereof a therapeutically effect amount of a suspension according to claim 1.
- 9) A method of treating a respiratory complaints disease, said method comprising administering to a patient in need thereof a therapeutically effect amount of a suspension according to claim 1.
- 10) The method according to claim 9, wherein the diseases are chosen from asthma and COPD.
Priority Claims (1)
Number |
Date |
Country |
Kind |
DE 102 14 263.7 |
Mar 2002 |
DE |
|
APPLICATION DATA
[0001] This application claims benefit to German application no. DE 102 14 263.7 filed Mar. 28, 2002 and U.S. provisional application No. 60/386,145 filed Jun. 5, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60386145 |
Jun 2002 |
US |